Clinical Trial Update: Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin [Phase 2]

View source ↗

Summary

A Phase 2 trial compares neoadjuvant tislelizumab plus lenvatinib versus surgery alone in stage Ia hepatocellular carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: HCC - Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING